Dutch enforcer issues first excessive pricing fine
The Dutch competition authority has fined Leadiant Biosciences €17.9 million for charging excessively high prices for a drug used to treat a rare genetic metabolic disorder, marking the first time it has ever imposed a penalty for such an infringement.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.